Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of FCF Margin readings, the most recent being 39.87% for Q1 2026.

  • On a quarterly basis, FCF Margin fell 259.0% to 39.87% in Q1 2026 year-over-year; TTM through Mar 2026 was 34.86%, a 1518.0% decrease, with the full-year FY2025 number at 35.42%, down 1324.0% from a year prior.
  • FCF Margin hit 39.87% in Q1 2026 for Catalyst Pharmaceuticals, up from 29.39% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 72.15% in Q3 2022 to a low of 14.05% in Q1 2023.
  • Median FCF Margin over the past 5 years was 43.88% (2023), compared with a mean of 42.3%.
  • Biggest five-year swings in FCF Margin: surged 2137bps in 2024 and later plummeted -3456bps in 2025.
  • Catalyst Pharmaceuticals' FCF Margin stood at 65.96% in 2022, then decreased by -24bps to 50.25% in 2023, then dropped by -1bps to 49.91% in 2024, then crashed by -41bps to 29.39% in 2025, then surged by 36bps to 39.87% in 2026.
  • The last three reported values for FCF Margin were 39.87% (Q1 2026), 29.39% (Q4 2025), and 21.86% (Q3 2025) per Business Quant data.